KR102793446B1 - Btk 억제제로서의 피롤로피리미딘 화합물 및 이의 용도 - Google Patents
Btk 억제제로서의 피롤로피리미딘 화합물 및 이의 용도 Download PDFInfo
- Publication number
- KR102793446B1 KR102793446B1 KR1020227018702A KR20227018702A KR102793446B1 KR 102793446 B1 KR102793446 B1 KR 102793446B1 KR 1020227018702 A KR1020227018702 A KR 1020227018702A KR 20227018702 A KR20227018702 A KR 20227018702A KR 102793446 B1 KR102793446 B1 KR 102793446B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- equiv
- added
- mixture
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911109773.2 | 2019-11-13 | ||
| CN201911109773 | 2019-11-13 | ||
| CN201911288492 | 2019-12-13 | ||
| CN201911288492.8 | 2019-12-13 | ||
| CN202010096582 | 2020-02-17 | ||
| CN202010096582.3 | 2020-02-17 | ||
| CN202010711270.9 | 2020-07-22 | ||
| CN202010711270 | 2020-07-22 | ||
| PCT/CN2020/128597 WO2021093839A1 (zh) | 2019-11-13 | 2020-11-13 | 作为btk抑制剂的吡咯并嘧啶类化合物及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220097455A KR20220097455A (ko) | 2022-07-07 |
| KR102793446B1 true KR102793446B1 (ko) | 2025-04-09 |
Family
ID=75912541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227018702A Active KR102793446B1 (ko) | 2019-11-13 | 2020-11-13 | Btk 억제제로서의 피롤로피리미딘 화합물 및 이의 용도 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12378253B2 (https=) |
| EP (1) | EP4059935A4 (https=) |
| JP (1) | JP7473642B2 (https=) |
| KR (1) | KR102793446B1 (https=) |
| CN (2) | CN117551103A (https=) |
| WO (1) | WO2021093839A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4234558A4 (en) * | 2020-12-07 | 2024-10-23 | Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. | PYRROLOPYRIDINE COMPOUND AND APPLICATION THEREOF |
| WO2022213932A1 (zh) * | 2021-04-06 | 2022-10-13 | 广州必贝特医药股份有限公司 | 吡咯并嘧啶酮类化合物及其应用 |
| CN114761410B (zh) * | 2021-04-06 | 2023-08-25 | 广州必贝特医药股份有限公司 | 吡咯并嘧啶酮类化合物及其应用 |
| EP4339198A4 (en) * | 2021-05-12 | 2025-06-11 | Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. | CRYSTAL FORM OF A PYRROLOPYRIMIDINE COMPOUND AND METHOD FOR PREPARING THE CRYSTAL FORM |
| KR20240157639A (ko) | 2021-12-14 | 2024-11-01 | 크로스파이어 온콜로지 홀딩 비.브이. | 거대고리 btk 억제제 |
| CN115894500B (zh) * | 2022-11-02 | 2024-05-28 | 中国药科大学 | 一种作为btk激酶抑制剂的化合物及其制备方法与用途 |
| CN118702697A (zh) * | 2023-03-18 | 2024-09-27 | 山东新时代药业有限公司 | 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法 |
| CN116375715B (zh) * | 2023-04-06 | 2025-04-04 | 中国药科大学 | 一种作为非共价btk激酶抑制剂的化合物及其生物用途 |
| WO2024245578A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor |
| WO2024245577A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor |
| WO2024246287A1 (en) | 2023-06-02 | 2024-12-05 | Crossfire Oncology Holding B.V. | Medical use of a macrocyclic reversible btk inhibitor |
| WO2024256568A1 (en) | 2023-06-13 | 2024-12-19 | Crossfire Oncology Holding B.V. | Salt and crystal forms of a macrocyclic btk inhibitor |
| WO2024256574A1 (en) | 2023-06-13 | 2024-12-19 | Crossfire Oncology Holding B.V. | Process for preparing macrocyclic btk inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI398252B (zh) * | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| EP3170825B1 (en) * | 2012-08-06 | 2019-04-10 | ACEA Biosciences Inc. | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases |
| EP3042903B1 (en) * | 2015-01-06 | 2019-08-14 | Impetis Biosciences Ltd. | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| SI3882250T1 (sl) * | 2015-12-23 | 2023-07-31 | Arqule, Inc. | Tetrahidropiranil amino-pirolopirimidinon za uporabo pri zdravljenju z BTK posredovanih motenj |
| TW201811795A (zh) * | 2016-08-24 | 2018-04-01 | 美商亞闊股份有限公司 | 胺基－吡咯并嘧啶酮化合物及其用途 |
-
2020
- 2020-11-13 JP JP2022528124A patent/JP7473642B2/ja active Active
- 2020-11-13 CN CN202311079865.7A patent/CN117551103A/zh not_active Withdrawn
- 2020-11-13 CN CN202080078768.4A patent/CN114728974B/zh active Active
- 2020-11-13 KR KR1020227018702A patent/KR102793446B1/ko active Active
- 2020-11-13 US US17/776,873 patent/US12378253B2/en active Active
- 2020-11-13 WO PCT/CN2020/128597 patent/WO2021093839A1/zh not_active Ceased
- 2020-11-13 EP EP20887944.5A patent/EP4059935A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4059935A1 (en) | 2022-09-21 |
| JP7473642B2 (ja) | 2024-04-23 |
| CN114728974A (zh) | 2022-07-08 |
| KR20220097455A (ko) | 2022-07-07 |
| EP4059935A4 (en) | 2024-02-28 |
| CN117551103A (zh) | 2024-02-13 |
| JP2023506691A (ja) | 2023-02-20 |
| US20230357248A1 (en) | 2023-11-09 |
| CN114728974B (zh) | 2023-09-19 |
| WO2021093839A1 (zh) | 2021-05-20 |
| US12378253B2 (en) | 2025-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102793446B1 (ko) | Btk 억제제로서의 피롤로피리미딘 화합물 및 이의 용도 | |
| CA3158749C (en) | PYRROLOTRIAZINE COMPOUNDS ACTING AS MNK INHIBITORS | |
| JP7374532B2 (ja) | 選択性の高いｒｏｓ１阻害剤としての化合物、及びその使用 | |
| CN113993860B (zh) | 作为kras g12c突变蛋白抑制剂的七元杂环类衍生物 | |
| US20250051330A1 (en) | Heterocyclic compound having anti-tumor activity and use thereof | |
| JP2011515370A (ja) | ４−アミノ−５−フルオロ−３−［５−（４−メチルピペラジン−１−イル）−１ｈ−ベンズイミダゾール−２−イル］キノリン−２（１ｈ）−オン乳酸塩の結晶形態及び２つの溶媒和物形態 | |
| JP7574450B2 (ja) | アミノピリジン系化合物及びその使用 | |
| CN116710460B (zh) | 联苯衍生物及其应用 | |
| CN114008046A (zh) | 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物 | |
| US12565481B2 (en) | 6,7-dimethoxy-3-(pyridin-2-yl)quinoline compounds for inhibiting RET | |
| CN114072401B (zh) | 作为irak4和btk多靶点抑制剂的噁唑类化合物 | |
| US8343977B2 (en) | Substituted triazolo-pyrimidine compounds | |
| CN116438175B (zh) | 苯并脲环衍生物及其制备方法和应用 | |
| AU2024289347A1 (en) | Nmt inhibitor, and preparation method therefor and use thereof | |
| JP7296017B2 (ja) | ベンゾスルタムを含む化合物 | |
| TW202330534A (zh) | 吡唑並環化合物及其應用 | |
| HK40080199A (en) | Pyrrolopyrimidine compound as btk inhibitor and use thereof | |
| CN113286594B (zh) | 吡啶并嘧啶类化合物在制备治疗鼻咽癌药物中的应用 | |
| CN118139865A (zh) | 吡咯并吡唑螺环化合物 | |
| CN116490504A (zh) | 吡咯并吡啶类化合物及其应用 | |
| CN116529249A (zh) | 吡啶并嘧啶酮类化合物 | |
| EA046344B1 (ru) | Соединение в качестве высокоселективного ингибитора ros1 и его применение | |
| HK40071305A (en) | Deuterated thienopyridine compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0105 | International application |
Patent event date: 20220602 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20220602 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20221013 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240812 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20250317 |
|
| PG1601 | Publication of registration |